ERBB2 and breast carcinoma: In a PANACEA trial, Pembrolizumab plus trastuzumab showed a clinical benefit in patients with PD-L1-positive, trastuzumab-resistant, advanced, HER2+ breast cancer, and in patients with increased TIL.